SELLAS Life Sciences (SLS) Stock Rockets 255% on Phase 3 AML Trial Progress

Key Takeaways

• SELLAS Life Sciences (SLS) stock has skyrocketed 255% in 2025 as investors anticipate Phase 3 REGAL trial results for galinpepimut-S, a treatment for acute myeloid leukemia
• The clinical trial has reached its 80-event milestone, triggering the final data analysis phase
• Recent research published in Haematologica indicates existing standard treatments may underperform expectations, potentially creating opportunities for SELLAS’s therapeutic candidate
• Institutional investors are increasing their stakes, including Quantinno Capital Management’s new $315,000 investment in Q1
• Wall Street maintains a “Hold” rating with a $10.00 price target, representing a significant discount to the current $15.46 trading level

SELLAS Life Sciences (SLS) stock began Monday’s session at $15.46, approaching its 52-week peak of $15.88, following an extraordinary year-to-date surge exceeding 255%. The biotech stock’s 52-week low stands at $1.39, highlighting the dramatic appreciation over recent months.

SELLAS Life Sciences Group, Inc., SLS

The primary driver behind this remarkable rally is progress in the Phase 3 REGAL clinical trial evaluating galinpepimut-S, the company’s investigational therapy for acute myeloid leukemia patients. The study has achieved the critical 80-event benchmark necessary to initiate final statistical analysis. This development has captured significant attention from market participants.

Compounding the bullish sentiment, recent findings published in the medical journal Haematologica indicate that current standard-of-care therapies for this indication may deliver less favorable outcomes than historically assumed. Should these observations prove valid, galinpepimut-S could face a more achievable efficacy threshold in the crowded leukemia treatment landscape.

Institutional capital has been steadily flowing into the stock. Quantinno Capital Management LP established a fresh position of 74,378 shares during the first quarter, representing approximately $315,000 in value. Additional institutional buyers include Larson Financial Group, BNP Paribas Financial Markets, Concurrent Investment Advisors, and Beacon Pointe Advisors.

In aggregate, institutional shareholders control 17.38% of outstanding shares. While this percentage remains modest, the upward trajectory signals growing confidence among professional investors.

Wall Street Coverage and Valuation Targets

Notwithstanding the stock’s impressive performance, analyst opinions remain divided. Alliance Global Partners maintains a Buy recommendation, most recently reiterated on August 12th. Conversely, Weiss Ratings holds a Sell rating (D-). The resulting consensus lands at “Hold” with a $10.00 price objective, approximately 35% beneath current trading levels.

SLS commands a market capitalization of $3.12 billion, posts a PE ratio of -73.62, and exhibits a beta coefficient of 2.48. The elevated beta metric reflects the stock’s pronounced volatility and sensitivity to market movements.

Financial Position and Key Risks

From a balance sheet perspective, SELLAS maintains minimal debt obligations and has strengthened its cash reserves, extending the operational runway for ongoing clinical development initiatives. The stock trades substantially above both its 50-day moving average of $11.85 and 200-day moving average of $7.75.

However, significant risks persist. The company generates zero commercial revenue, continues to consume cash, and regularly dilutes shareholders through equity financing. An unfavorable arbitration decision represents another overhang. Most recently, quarterly earnings per share registered at -$0.05, falling short of the -$0.04 consensus estimate.

The investment thesis rests entirely on forthcoming REGAL trial outcomes. At $15.46 per share, the market has embedded substantial optimistic expectations that remain unvalidated.

The Street’s $10.00 consensus target continues to imply meaningful downside from present levels.